MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
About MARAVAI LIFESCIENCES HOLDINGS, INC.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $185.7M
- Net income
- -$130.8M
- Total assets
- $770.6M
- Market cap
- $740.5M
- Gross margin
- 18.3%
- Operating margin
- -115.9%
- Net margin
- -124.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $185.7M
- Cost of revenue
- $151.8M
- Gross profit
- $34.0M
- Operating expenses
- $249.3M
- Operating income
- -$215.3M
- Income tax
- -$4.2M
- Net income
- -$230.8M
- EPS (basic)
- $-0.90
- EPS (diluted)
- $-0.90
Balance sheet
- Total assets
- $770.6M
- Current assets
- $296.3M
- Total liabilities
- $397.9M
- Current liabilities
- $44.9M
- Shareholders’ equity
- $372.7M
Cash flow
- Operating cash flow
- -$57.6M
- Investing cash flow
- -$31.4M
- Financing cash flow
- -$16.5M
- Net cash flow
- -$105.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $740.5M
- EPS (diluted)
- $-0.9
- Shares outstanding
- 109.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 20, 2020
Maravai Lifesciences Holdings, Inc. (MRVI) Stock Price
- Reported a net loss of $130.8M in FY2025.
- Revenue declined 77% from FY2021 to FY2025.
- Gross margin of 18.3%, net margin -124.2%.
- Trading 7% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MARAVAI LIFESCIENCES HOLDINGS, INC..
Write a review
News about MARAVAI LIFESCIENCES HOLDINGS, INC.
News & sentiment via Polygon.io
Maravai Lifesciences Holdings, Inc.: frequently asked questions
Is Maravai Lifesciences Holdings, Inc. an American company?
Maravai Lifesciences Holdings, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Maravai Lifesciences Holdings, Inc. headquartered?
Maravai Lifesciences Holdings, Inc. is headquartered in San Diego, California, United States.
Is Maravai Lifesciences Holdings, Inc. publicly traded?
Yes — Maravai Lifesciences Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol MRVI on the NASDAQ.
What does Maravai Lifesciences Holdings, Inc. do?
Maravai Lifesciences Holdings, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
